{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:44:12Z","timestamp":1759365852764,"version":"build-2065373602"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00393-025-01699-9","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T13:13:48Z","timestamp":1755782028000},"page":"639-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Studienlage und aktualisierte Leitlinie der European Society for Blood and Marrow Transplantation zur autologen h\u00e4matopoetischen Stammzelltransplantation bei entz\u00fcndlich rheumatischen Erkrankungen","Evidence and updated guidelines of the European Society for Blood and Marrow Transplantation on autologous hematopoietic stem cell transplantation in inflammatory rheumatic diseases"],"prefix":"10.1007","volume":"84","author":[{"given":"Tobias","family":"Alexander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"1699_CR1","doi-asserted-by":"crossref","unstructured":"Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, \u010coli\u0107 J, Santiago T, Suliman YA, Matucci-Cerinic M, Gabrielli A, Distler O et al (2025) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 84(1):29\u201340","DOI":"10.1136\/ard-2024-226430"},{"issue":"1","key":"1699_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Andersen\u00a0J, Aringer\u00a0M, Arnaud\u00a0L, Bae\u00a0S\u2011C, Boletis\u00a0J, Bruce\u00a0IN, Cervera\u00a0R, Doria\u00a0A et\u00a0al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83(1):15\u201329","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1699_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich\u00a0B, Sanchez-Alamo\u00a0B, Schirmer\u00a0JH, Berti\u00a0A, Blockmans\u00a0D, Cid\u00a0MC, Holle\u00a0JU, Hollinger\u00a0N, Karadag\u00a0O, Kronbichler\u00a0A et\u00a0al (2024) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 83(1):30\u201347","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1699_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen\u00a0JS, Landew\u00e9\u00a0RBM, Bergstra\u00a0SA, Kerschbaumer\u00a0A, Sepriano\u00a0A, Aletaha\u00a0D, Caporali\u00a0R, Edwards\u00a0CJ, Hyrich\u00a0KL, Pope\u00a0JE et\u00a0al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1699_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41584-021-00601-6","volume":"17","author":"P Maschmeyer","year":"2021","unstructured":"Maschmeyer\u00a0P, Chang\u00a0HD, Cheng\u00a0Q, Mashreghi\u00a0MF, Hiepe\u00a0F, Alexander\u00a0T, Radbruch\u00a0A (2021) Immunological memory in rheumatic inflammation\u2014a\u00a0roadblock to tolerance induction. Nat Rev Rheumatol 17(5):291\u2013305","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"1699_CR6","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/s41409-022-01702-w","volume":"57","author":"T Alexander","year":"2022","unstructured":"Alexander\u00a0T, Greco\u00a0R (2022) Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 57(7):1055\u20131062","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"1699_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrrheum.2017.7","volume":"13","author":"JF Swart","year":"2017","unstructured":"Swart\u00a0JF, Delemarre\u00a0EM, van Wijk\u00a0F, Boelens\u00a0JJ, Kuball\u00a0J, van Laar\u00a0JM, Wulffraat\u00a0NM (2017) Haematopoietic stem cell transplantation for autoimmune diseases. Nat Rev Rheumatol 13(4):244\u2013256","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"1699_CR8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","volume":"57","author":"JA Snowden","year":"2022","unstructured":"Snowden\u00a0JA, Sanchez-Ortega\u00a0I, Corbacioglu\u00a0S, Basak\u00a0GW, Chabannon\u00a0C, de la Camara\u00a0R, Dolstra\u00a0H, Duarte\u00a0RF, Glass\u00a0B, Greco\u00a0R et\u00a0al (2022) Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 57(8):1217\u20131239","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"1699_CR9","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/bmt.2011.185","volume":"47","author":"JA Snowden","year":"2012","unstructured":"Snowden\u00a0JA, Saccardi\u00a0R, Allez\u00a0M, Ardizzone\u00a0S, Arnold\u00a0R, Cervera\u00a0R, Denton\u00a0C, Hawkey\u00a0C, Labopin\u00a0M, Mancardi\u00a0G et\u00a0al (2012) Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 47(6):770\u2013790","journal-title":"Bone Marrow Transplant"},{"key":"1699_CR10","doi-asserted-by":"crossref","unstructured":"Alexander T, Roldan E, Del Papa N, Farge D, Henes J, Marjanovic Z, Puyade M, Snowden JA, Spierings J, de Vries-Bouwstra J et\u00a0al (2025) Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines committee. Bone Marrow Transplant (in press)","DOI":"10.1038\/s41409-025-02695-y"},{"issue":"6","key":"1699_CR11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41409-023-01958-w","volume":"58","author":"I Yakoub-Agha","year":"2023","unstructured":"Yakoub-Agha\u00a0I, Greco\u00a0R, Onida\u00a0F, de la Camara\u00a0R, Ciceri\u00a0F, Corbacioglu\u00a0S, Dolstra\u00a0H, Glass\u00a0B, Kenyon\u00a0M, McLornan\u00a0DP et\u00a0al (2023) Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transplant 58(6):696\u2013700","journal-title":"Bone Marrow Transplant"},{"issue":"27","key":"1699_CR12","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","volume":"1","author":"JA Snowden","year":"2017","unstructured":"Snowden\u00a0JA, Badoglio\u00a0M, Labopin\u00a0M, Giebel\u00a0S, McGrath\u00a0E, Marjanovic\u00a0Z, Burman\u00a0J, Moore\u00a0J, Rovira\u00a0M, Wulffraat\u00a0NM et\u00a0al (2017) Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv 1(27):2742\u20132755","journal-title":"Blood Adv"},{"key":"1699_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1146\/annurev-med-070119-115617","volume":"72","author":"T Alexander","year":"2021","unstructured":"Alexander\u00a0T, Greco\u00a0R, Snowden\u00a0JA (2021) Hematopoietic Stem Cell Transplantation for Autoimmune Disease. Annu Rev Med 72:215\u2013228","journal-title":"Annu Rev Med"},{"issue":"2","key":"1699_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2009.013458","volume":"95","author":"D Farge","year":"2010","unstructured":"Farge\u00a0D, Labopin\u00a0M, Tyndall\u00a0A, Fassas\u00a0A, Mancardi\u00a0GL, Van Laar\u00a0J, Ouyang\u00a0J, Kozak\u00a0T, Moore\u00a0J, Kotter\u00a0I et\u00a0al (2010) Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12\u00a0years\u2019 experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 95(2):284\u2013292","journal-title":"Haematologica"},{"issue":"8","key":"1699_CR15","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1136\/annrheumdis-2020-217058","volume":"79","author":"S van Bijnen","year":"2020","unstructured":"van Bijnen\u00a0S, de Vries-Bouwstra\u00a0J, van den Ende\u00a0CH, Boonstra\u00a0M, Kroft\u00a0L, Geurts\u00a0B, Snoeren\u00a0M, Schouffoer\u00a0A, Spierings\u00a0J, van Laar\u00a0JM et\u00a0al (2020) Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a\u00a0long-term follow-up multicentre study. Ann Rheum Dis 79(8):1084\u20131089","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1699_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","volume":"84","author":"F Del Galdo","year":"2025","unstructured":"Del Galdo\u00a0F, Lescoat\u00a0A, Conaghan\u00a0PG, Bertoldo\u00a0E, Colic\u00a0J, Santiago\u00a0T, Suliman\u00a0YA, Matucci-Cerinic\u00a0M, Gabrielli\u00a0A, Distler\u00a0O et\u00a0al (2025) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 84(1):29\u201340","journal-title":"Ann Rheum Dis"},{"issue":"9790","key":"1699_CR17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt\u00a0RK, Shah\u00a0SJ, Dill\u00a0K, Grant\u00a0T, Gheorghiade\u00a0M, Schroeder\u00a0J, Craig\u00a0R, Hirano\u00a0I, Marshall\u00a0K, Ruderman\u00a0E et\u00a0al (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase\u00a02\u00a0trial. Lancet 378(9790):498\u2013506","journal-title":"Lancet"},{"issue":"1","key":"1699_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan\u00a0KM, Goldmuntz\u00a0EA, Keyes-Elstein\u00a0L, McSweeney\u00a0PA, Pinckney\u00a0A, Welch\u00a0B, Mayes\u00a0MD, Nash\u00a0RA, Crofford\u00a0LJ, Eggleston\u00a0B et\u00a0al (2018) Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N\u00a0Engl J Med 378(1):35\u201347","journal-title":"N Engl J Med"},{"issue":"24","key":"1699_CR19","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar\u00a0JM, Farge\u00a0D, Sont\u00a0JK, Naraghi\u00a0K, Marjanovic\u00a0Z, Larghero\u00a0J, Schuerwegh\u00a0AJ, Marijt\u00a0EW, Vonk\u00a0MC, Schattenberg\u00a0AV et\u00a0al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a\u00a0randomized clinical trial. JAMA 311(24):2490\u20132498","journal-title":"JAMA"},{"issue":"11","key":"1699_CR20","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bmt.2017.56","volume":"52","author":"D Farge","year":"2017","unstructured":"Farge\u00a0D, Burt\u00a0RK, Oliveira\u00a0MC, Mousseaux\u00a0E, Rovira\u00a0M, Marjanovic\u00a0Z, de Vries-Bouwstra\u00a0J, Del Papa\u00a0N, Saccardi\u00a0R, Shah\u00a0SJ et\u00a0al (2017) Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplant 52(11):1495\u20131503","journal-title":"Bone Marrow Transplant"},{"issue":"SI","key":"1699_CR21","doi-asserted-by":"publisher","first-page":"SI107","DOI":"10.1093\/rheumatology\/keac455","volume":"62","author":"AC Pecher","year":"2023","unstructured":"Pecher\u00a0AC, Ach\u00a0KR, Vogel\u00a0W, Henes\u00a0JC (2023) Mobilization with reduced cyclophosphamide for autologous stem cell transplantation is feasible in patients with systemic sclerosis. Rheumatol 62(SI):SI107\u2013SI113","journal-title":"Rheumatol"},{"issue":"1","key":"1699_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41409-020-0978-2","volume":"56","author":"RK Burt","year":"2021","unstructured":"Burt\u00a0RK, Han\u00a0X, Quigley\u00a0K, Arnautovic\u00a0I, Shah\u00a0SJ, Lee\u00a0DC, Freed\u00a0BH, Jovanovic\u00a0B, Helenowski\u00a0IB (2021) Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a\u00a0pilot safety study that decreases neutropenic interval to 5\u00a0days. Bone Marrow Transplant 56(1):50\u201359","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"1699_CR23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/rheumatology\/ket464","volume":"53","author":"JC Henes","year":"2014","unstructured":"Henes\u00a0JC, Koetter\u00a0I, Horger\u00a0M, Schmalzing\u00a0M, Mueller\u00a0K, Eick\u00a0C, Bauer\u00a0A, Vogel\u00a0W, Kanz\u00a0L (2014) Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. Rheumatol 53(5):919\u2013922","journal-title":"Rheumatol"},{"issue":"2","key":"1699_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2019.230128","volume":"106","author":"J Henes","year":"2021","unstructured":"Henes\u00a0J, Oliveira\u00a0MC, Labopin\u00a0M, Badoglio\u00a0M, Scherer\u00a0HU, Del Papa\u00a0N, Daikeler\u00a0T, Schmalzing\u00a0M, Schroers\u00a0R, Martin\u00a0T et\u00a0al (2021) Autologous stem cell transplantation for progressive systemic sclerosis: a\u00a0prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica 106(2):375\u2013383","journal-title":"Haematologica"},{"issue":"1","key":"1699_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan\u00a0KM, Goldmuntz\u00a0EA, Keyes-Elstein\u00a0L, McSweeney\u00a0PA, Pinckney\u00a0A, Welch\u00a0B, Mayes\u00a0MD, Nash\u00a0RA, Crofford\u00a0LJ, Eggleston\u00a0B et\u00a0al (2018) Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N\u00a0Engl J Med 378(1):35\u201347","journal-title":"N Engl J Med"},{"issue":"4","key":"1699_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/bmt.2015.299","volume":"51","author":"MC Oliveira","year":"2016","unstructured":"Oliveira\u00a0MC, Labopin\u00a0M, Henes\u00a0J, Moore\u00a0J, Del Papa\u00a0N, Cras\u00a0A, Sakellari\u00a0I, Schroers\u00a0R, Scherer\u00a0HU, Cuneo\u00a0A et\u00a0al (2016) Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? Bone Marrow Transplant 51(4):501\u2013505","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"1699_CR27","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1136\/annrheumdis-2019-215145","volume":"78","author":"M Becker","year":"2019","unstructured":"Becker\u00a0M, Graf\u00a0N, Sauter\u00a0R, Allanore\u00a0Y, Curram\u00a0J, Denton\u00a0CP, Khanna\u00a0D, Matucci-Cerinic\u00a0M, de Oliveira\u00a0PJ, Pope\u00a0JE et\u00a0al (2019) Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a\u00a0European Scleroderma Trials and Research (EUSTAR) analysis. Ann Rheum Dis 78(9):1242\u20131248","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1699_CR28","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai\u00a0M, Meune\u00a0C, Boubaya\u00a0M, Avouac\u00a0J, Hachulla\u00a0E, Balbir-Gurman\u00a0A, Riemekasten\u00a0G, Airo\u00a0P, Joven\u00a0B, Vettori\u00a0S et\u00a0al (2017) Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 76(11):1897\u20131905","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1699_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1191\/0961203304lu525oa","volume":"13","author":"D Jayne","year":"2004","unstructured":"Jayne\u00a0D, Passweg\u00a0J, Marmont\u00a0A, Farge\u00a0D, Zhao\u00a0X, Arnold\u00a0R, Hiepe\u00a0F, Lisukov\u00a0I, Musso\u00a0M, Ou-Yang\u00a0J et\u00a0al (2004) Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13(3):168\u2013176","journal-title":"Lupus"},{"issue":"3","key":"1699_CR30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/0961203312470729","volume":"22","author":"B Alchi","year":"2013","unstructured":"Alchi\u00a0B, Jayne\u00a0D, Labopin\u00a0M, Demin\u00a0A, Sergeevicheva\u00a0V, Alexander\u00a0T, Gualandi\u00a0F, Gruhn\u00a0B, Ouyang\u00a0J, Rzepecki\u00a0P et\u00a0al (2013) Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry. Lupus 22(3):245\u2013253","journal-title":"Lupus"},{"issue":"5","key":"1699_CR31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jama.295.5.527","volume":"295","author":"RK Burt","year":"2006","unstructured":"Burt\u00a0RK, Traynor\u00a0A, Statkute\u00a0L, Barr\u00a0WG, Rosa\u00a0R, Schroeder\u00a0J, Verda\u00a0L, Krosnjar\u00a0N, Quigley\u00a0K, Yaung\u00a0K et\u00a0al (2006) Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 295(5):527\u2013535","journal-title":"JAMA"},{"issue":"6","key":"1699_CR32","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s41409-018-0173-x","volume":"53","author":"RK Burt","year":"2018","unstructured":"Burt\u00a0RK, Han\u00a0X, Gozdziak\u00a0P, Yaung\u00a0K, Morgan\u00a0A, Clendenan\u00a0AM, Henry\u00a0J, Calvario\u00a0MA, Datta\u00a0SK, Helenowski\u00a0I et\u00a0al (2018) Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome. Bone Marrow Transplant 53(6):692\u2013700","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"1699_CR33","first-page":"482","volume":"31","author":"JA Snowden","year":"2004","unstructured":"Snowden\u00a0JA, Passweg\u00a0J, Moore\u00a0JJ, Milliken\u00a0S, Cannell\u00a0P, Van Laar\u00a0J, Verburg\u00a0R, Szer\u00a0J, Taylor\u00a0K, Joske\u00a0D et\u00a0al (2004) Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a\u00a0report from the EBMT and ABMTR. J\u00a0Rheumatol 31(3):482\u2013488","journal-title":"J Rheumatol"},{"issue":"12","key":"1699_CR34","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/sj.bmt.1702435","volume":"25","author":"F Lanza","year":"2000","unstructured":"Lanza\u00a0F, Dominici\u00a0M, Govoni\u00a0M, Moretti\u00a0S, Campioni\u00a0D, Corte\u00a0RL, Latorraca\u00a0A, Tieghi\u00a0A, Castagnari\u00a0B, Trotta\u00a0F et\u00a0al (2000) Prolonged remission state of refractory adult onset Still\u2019s disease following CD34-selected autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 25(12):1307\u20131310","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"1699_CR35","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41409-019-0763-2","volume":"55","author":"T Alexander","year":"2020","unstructured":"Alexander\u00a0T, Samuelson\u00a0C, Daikeler\u00a0T, Henes\u00a0J, Akil\u00a0M, Skagerlind\u00a0L, Ehninger\u00a0G, Jantunen\u00a0E, Badoglio\u00a0M, Farge\u00a0D et\u00a0al (2020) Autologous haematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a\u00a0retrospective survey of patients reported to European Society for Blood and Marrow Transplantation (EBMT) registry. Bone Marrow Transplant 55(7):1512\u20131515","journal-title":"Bone Marrow Transplant"},{"key":"1699_CR36","doi-asserted-by":"publisher","first-page":"638709","DOI":"10.3389\/fimmu.2021.638709","volume":"12","author":"M Puyade","year":"2021","unstructured":"Puyade\u00a0M, Patel\u00a0A, Lim\u00a0YJ, Blank\u00a0N, Badoglio\u00a0M, Gualandi\u00a0F, Ma\u00a0DD, Maximova\u00a0N, Greco\u00a0R, Alexander\u00a0T et\u00a0al (2021) Autologous Hematopoietic Stem Cell Transplantation for Beh\u00e7et\u2019s Disease: A\u00a0Retrospective Survey of Patients Treated in Europe, on Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation. Front Immunol 12:638709","journal-title":"Front Immunol"},{"issue":"24","key":"1699_CR37","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher\u00a0AC, Hensen\u00a0L, Klein\u00a0R, Schairer\u00a0R, Lutz\u00a0K, Atar\u00a0D, Seitz\u00a0C, Stanger\u00a0A, Schneider\u00a0J, Braun\u00a0C et\u00a0al (2023) CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome. JAMA 329(24):2154\u20132162","journal-title":"JAMA"},{"issue":"8","key":"1699_CR38","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller\u00a0F, Taubmann\u00a0J, Bucci\u00a0L, Wilhelm\u00a0A, Bergmann\u00a0C, V\u00f6lkl\u00a0S, Aigner\u00a0M, Rothe\u00a0T, Minopoulou\u00a0I, Tur\u00a0C et\u00a0al (2024) CD19 CAR T\u2011Cell Therapy in Autoimmune Disease\u2014A Case Series with Follow-up. N\u00a0Engl J Med 390(8):687\u2013700","journal-title":"N Engl J Med"},{"key":"1699_CR39","doi-asserted-by":"crossref","unstructured":"Auth J, M\u00fcller F, V\u00f6lkl S, Bayerl N, Distler JHW, Tur C, Raimondo MG, Chenguiti Fakhouri S, Atzinger A, Coppers B et\u00a0al (2024) CD19-targeting CAR T\u2011cell therapy in patients with diffuse systemic sclerosis: a\u00a0case series. Lancet Rheumatol","DOI":"10.1016\/S2665-9913(24)00282-0"},{"issue":"3","key":"1699_CR40","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","volume":"84","author":"I Minopoulou","year":"2025","unstructured":"Minopoulou\u00a0I, Wilhelm\u00a0A, Albach\u00a0F, Kleyer\u00a0A, Wiebe\u00a0E, Schallenberg\u00a0S, Fleischmann\u00a0A, Frick\u00a0M, Damm\u00a0F, Gogolok\u00a0J et\u00a0al (2025) Anti-CD19 CAR T\u00a0cell therapy induces antibody seroconversion and complete B\u00a0cell depletion in the bone marrow of a\u00a0therapy-refractory patient with ANCA-associated vasculitis. Ann Rheum Dis 84(3):e4\u2013e7","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1699_CR41","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1093\/rheumatology\/keaf077","volume":"64","author":"FN Albach","year":"2025","unstructured":"Albach\u00a0FN, Minopoulou\u00a0I, Wilhelm\u00a0A, Biesen\u00a0R, Kleyer\u00a0A, Wiebe\u00a0E, Fleischmann\u00a0A, Frick\u00a0M, Damm\u00a0F, Gogolok\u00a0J et\u00a0al (2025) Targeting autoimmunity with CD19-CAR T\u2011cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis. Rheumatol 64(6):4075\u20134077","journal-title":"Rheumatol"},{"key":"1699_CR42","doi-asserted-by":"crossref","unstructured":"M\u00fcller F, Wirsching A, Hagen M, V\u00f6lkl S, Tur C, Raimondo MG, Taubmann J, Bucci L, Zhang L, Kretschmann S et\u00a0al (2025) BCMA CAR T\u00a0cells in a\u00a0patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T\u00a0cells. Nat Med","DOI":"10.1038\/s41591-025-03718-3"},{"key":"1699_CR43","doi-asserted-by":"publisher","first-page":"114071","DOI":"10.1016\/j.ejca.2024.114071","volume":"204","author":"M Subklewe","year":"2024","unstructured":"Subklewe\u00a0M, Magno\u00a0G, Gebhardt\u00a0C, B\u00fccklein\u00a0V, Szelinski\u00a0F, Ar\u00e9valo\u00a0HJR, H\u00e4nel\u00a0G, D\u00f6rner\u00a0T, Zugmaier\u00a0G, von Bergwelt-Baildon\u00a0M et\u00a0al (2024) Application of blinatumomab, a\u00a0bispecific anti-CD3\/CD19 T\u2011cell engager, in treating severe systemic sclerosis: A\u00a0case study. Eur J Cancer 204:114071","journal-title":"Eur J Cancer"},{"issue":"6","key":"1699_CR44","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci\u00a0L, Hagen\u00a0M, Rothe\u00a0T, Raimondo\u00a0MG, Fagni\u00a0F, Tur\u00a0C, Wirsching\u00a0A, Wacker\u00a0J, Wilhelm\u00a0A, Auger\u00a0JP et\u00a0al (2024) Bispecific T\u00a0cell engager therapy for refractory rheumatoid arthritis. Nat Med 30(6):1593\u20131601","journal-title":"Nat Med"},{"issue":"9","key":"1699_CR45","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc2407150","volume":"391","author":"T Alexander","year":"2024","unstructured":"Alexander\u00a0T, Kr\u00f6nke\u00a0J, Cheng\u00a0Q, Keller\u00a0U, Kr\u00f6nke\u00a0G (2024) Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus. N\u00a0Engl J Med 391(9):864\u2013866","journal-title":"N Engl J Med"},{"issue":"9","key":"1699_CR46","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen\u00a0M, Bucci\u00a0L, B\u00f6ltz\u00a0S, N\u00f6thling\u00a0DM, Rothe\u00a0T, Anoshkin\u00a0K, Raimondo\u00a0MG, Tur\u00a0C, Wirsching\u00a0A, Wacker\u00a0J et\u00a0al (2024) BCMA-Targeted T\u2011Cell-Engager Therapy for Autoimmune Disease. N\u00a0Engl J Med 391(9):867\u2013869","journal-title":"N Engl J Med"},{"key":"1699_CR47","doi-asserted-by":"crossref","unstructured":"Siegert E, Biesen R, Dzamukova M, Furth C, Probst M, Doellinger F, Walter-Rittel T, Fleischmann A, Wilhelm A, Beenken AE et\u00a0al (2025) Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation. Ann Rheum Dis","DOI":"10.1016\/j.ard.2025.01.043"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01699-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:10:26Z","timestamp":1759317026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01699-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1699"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01699-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"30 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Alexander erhielt Honorare von AbbVie, Amgen, AstraZeneca, GSK und Neovii und Studienunterst\u00fctzung von Amgen, Miltenyi und Janssen CILAG. M.\u00a0Schmalzing erhielt Honorare f\u00fcr Berater- und Gutachtert\u00e4tigkeit: AbbVie, Alfasigma\/Galapagos, AstraZeneca, BMS, Boehringer Ingelheim, EUSA-Pharma\/Recordati, Johnson\u00a0&\u00a0Johnson, Novartis, onkowissen.de, Sanofi, SOBI, UCB sowie Vortrags- und Schulungst\u00e4tigkeit: AbbVie, Alfasigma\/Galapagos, BMS, Boehringer Ingelheim, EUSA-Pharma\/Recordati, Johnson\u00a0&\u00a0Johnson, Lilly, Merck, Novartis, onkowissen.de, Pfizer und f\u00fcr Kongressteilnahmen: AbbVie, Alfasigma\/Galapagos, Boehringer Ingelheim, Johnson\u00a0&\u00a0Johnson, UCB und Forschungsunterst\u00fctzung von: Chugai, Novartis, AbbVie. J.\u00a0Henes erhielt Honorare von AbbVie, AstraZeneca, Boehringer Ingelheim, BMS, Johnson\u00a0&\u00a0Johnson, Lilly, Novartis, Pfizer, Roche, SOBI, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}